Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Genetically Engineered Cells (ATLCAR.CD30) for the Treatment of Patients with Refractory or Relapsed CD30+ Nonseminomatous Germ Cell Tumors

Trial Status: active

This phase II trial tests how well autologous CD30CAR-CD28-CD3zeta-expressing T-lymphocytes (ATLCAR.CD30) works in treating patients with nonseminomatous germ cell tumors that do not respond to treatment (refractory) or that have come back after a period of improvement (relapsed/recurrent). Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. ATLCAR.CD30 cells may be effective at treating patients with refractory or relapsed nonseminomatous germ cell tumors.